Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Immune Design Corp. (NASDAQ: IMDZ).

Full DD Report for IMDZ

You must become a subscriber to view this report.


Recent News from (NASDAQ: IMDZ)

Lucky Seven: Immune Design Takes Off, Institutions Place Bets On Viking Therapeutics
Lucky Seven The Lucky Seven is a swing-trading biotechnology portfolio of seven stocks listed in a way to reflect top picks and risk tolerance. The first three picks are the top picks (in no particular order). Risks are increased the further away a stock sits from #4 (the least risky stoc...
Source: SeekingAlpha
Date: May, 16 2018 03:55
Lucky Seven: Achaogen Likely To Bounce Back
The biotechnology sector ( XBI ) felt good about itself last week. As a result, many of the promising, up-and-coming biotechnology companies saw investors throwing their cash back at them in hopes of profitable returns. We anticipate the trend will continue, at least for a short time: C...
Source: SeekingAlpha
Date: May, 14 2018 08:19
Lucky Seven: Omeros Pops, Exelixis Drops On Phase 3 Flop
Thursday and Friday were eventful days for the Lucky Seven and for biotechnology stocks, in general. It requires portfolio reassessment. First, Some Guidelines Before we begin, I'd like to discuss some additional key points to the purpose of the Lucky Seven portfolio: The goal, for all...
Source: SeekingAlpha
Date: May, 12 2018 00:23
Immune Design Nearing Critical Point In Valuation
Immune Design (IMDZ) is up 15% since I penned my thesis article in early February. Overview This immuno-oncology play has been virtually stagnant all year. This is despite a ridiculous amount of insider buys (akin to what took place with a similar company, ADAP ) after the share price...
Source: SeekingAlpha
Date: May, 11 2018 15:03
Complimentary Stock Performance Review on La Jolla Pharma and Three Additional Biotech Industry Stocks
Stock Research Monitor: IMDZ, IMUC, and LXRX LONDON, UK / ACCESSWIRE / May 11, 2018 / If you want a free Stock Review on LJPC sign up now at www.wallstequities.com/registration . On Thursday, the NASDAQ Composite ended the day at 7,404.97, up 0.89%; the Dow Jones Industrial Averag...
Source: ACCESSWIRE IA
Date: May, 11 2018 07:05
Lucky Seven: Omeros Moves, Array Biopharma May Be Next
iShares Nasdaq Biotechnology ETF ( IBB ) was good for a 0.3% gain within the last three trading days, while the Lucky Seven netted a 2.6% gain. The Lucky Seven portfolio assumes an investor made a $1000 investment, to begin, in each pick. So, the portfolio began with $7,000. Lucky Seven ...
Source: SeekingAlpha
Date: May, 08 2018 15:02
Lucky Seven: An Introduction To My Top Biotechnology Picks
Introduction I am a Registered Nurse, currently advancing my education at Purdue University. I work on an intermediate care unit in a hospital where I am responsible for the care and lives of folks who come to me with a myriad of medical conditions. I hope to soon become a nursing professor....
Source: SeekingAlpha
Date: May, 03 2018 05:28
Immune Design's (IMDZ) CEO Dr. Carlos Paya on Q1 2018 Results - Earnings Call Transcript
Immune Design Corp. (IMDZ) Q1 2018 Results Earnings Conference Call May 2, 2018, 4:30 PM ET Executives Sylvia Wheeler - Investor Relations Group Dr. Carlos Paya - President and CEO Steve Brady - Executive Vice President, Strategy and Finance Dr. Sergey Yurasov - Senior Vice Pre...
Source: SeekingAlpha
Date: May, 02 2018 23:17
Immune Design beats by $0.01, misses on revenue
Immune Design (NASDAQ: IMDZ ): Q1 EPS of -$0.28 beats by $0.01 . More news on: Immune Design, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: May, 02 2018 16:13
Immune Design Reports First Quarter 2018 Financial Results and Provides Corporate Update
The higher dose of CMB305 was deemed safe and cleared for the pivotal Phase 3 The 20ug dose of G100 shows a two-fold increase in TILs, higher than that seen at the 10ug dose Conference call at 1:30 pm Pacific today SEATTLE and SOUTH SAN FRANCISCO, Calif., May 02, 2018 (GLOB...
Source: GlobeNewswire
Date: May, 02 2018 16:01

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-174.504.454.504.15375,623
2017-02-035.405.705.755.4030,752
2017-02-025.605.355.705.3059,648
2017-02-015.805.655.955.6039,925
2017-01-315.555.655.755.4542,309

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-2146,469102,01645.5507Short
2018-05-1812,19150,29524.2390Cover
2018-05-1758,064137,58042.2038Short
2018-05-16113,328328,91834.4548Cover
2018-05-1582,562297,51627.7504Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on IMDZ.


About Immune Design Corp. (NASDAQ: IMDZ)

Logo for Immune Design Corp. (NASDAQ: IMDZ)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: IMDZ)

      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 03 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 02 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 26 2018
      Written public communication relating to an issuer or third party tender offer not by the subject company
      Filing Type: SC TO-CFiling Source: edgar
      Filing Date: April, 26 2018
      Preliminary proxy statement providing notification matters to be brought to a vote
      Filing Type: PRE 14AFiling Source: edgar
      Filing Date: April, 10 2018
      Written public communication relating to an issuer or third party tender offer not by the subject company
      Filing Type: SC TO-CFiling Source: edgar
      Filing Date: April, 10 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 14 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 14 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: March, 14 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 14 2018

       

       


      Daily Technical Chart for (NASDAQ: IMDZ)

      Daily Technical Chart for (NASDAQ: IMDZ)


      Stay tuned for daily updates and more on (NASDAQ: IMDZ)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: IMDZ)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      Monsta Trader
      @MonstaTrader

       

       


      Disclaimer: Monsta Trader publishes reports providing information on selected companies. Monsta Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. Monsta Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in IMDZ is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Monsta Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. Monsta Trader does not own any shares of IMDZ and does not buy, sell, or trade any shares of IMDZ. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by Monsta Trader. All rights reserved. Our Full Disclaimer: http://monstatrader.com/disclaimer/